Extensive Stage Small Cell Lung Cancer Pipeline Review | Clinical Trial Analysis by DelveInsight

2022年05月17日01:00

First-line therapies in the treatment of Extensive Stage Small Cell Lung Cancer (ES-SCLC) currently consist of chemotherapy, combining a platinum drug with either etoposide or irinotecan as a possible alternative. New treatments are under development in order to improve the prognosis of ES-SCLC. There are approximately more than 35+ companies investigating the potential therapies for the treatment of ES-SCLC including Bristol-Myers Squibb, Shanghai Henlius Biotech, Jiangsu HengRui Medicine, BeiGene, Hoffmann-La Roche, Lee's Pharmaceutical, and several others.

New York, USA, May 16, 2022 (GLOBE NEWSWIRE) -- Extensive Stage Small Cell Lung Cancer Pipeline Review | Clinical Trial Analysis by DelveInsight

First-line therapies in the treatment of Extensive Stage Small Cell Lung Cancer (ES-SCLC) currently consist of chemotherapy, combining a platinum drug with either etoposide or irinotecan as a possible alternative. New treatments are under development in order to improve the prognosis of ES-SCLC. There are approximately more than 35+ companies investigating the potential therapies for the treatment of ES-SCLC including Bristol-Myers Squibb, Shanghai Henlius Biotech, Jiangsu HengRui Medicine, BeiGene, Hoffmann-La Roche, Lee's Pharmaceutical, and several others.

DelveInsight’s 'Extensive Stage Small Cell Lung Cancer Pipeline Insight 2022' report provides comprehensive global coverage of available, marketed, and pipeline Extensive Stage Small Cell Lung Cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Extensive Stage Small Cell Lung Cancer pipeline domain.

Key Takeaways from the Extensive Stage Small Cell Lung Cancer Pipeline Report

  • DelveInsight’s Extensive Stage Small Cell Lung Cancer Pipeline report depicts a robust space with 35+ active players working to develop 38+ pipeline therapies for Extensive Stage Small Cell Lung Cancer treatment.
  • Leading Extensive Stage Small Cell Lung Cancer companies such as Genentech, Bristol-Myers Squibb, Henilus Biotech, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., BioNTech SE, Xencor, Inc., Haihe Biopharma Co., Ltd., Taizhou HoudeAoke Biomedical Co., Ltd., Celgene, Xcovery Holding Company, LLC, Lee's Pharmaceutical Limited, Merck & Co, Astex Pharmaceuticals, Daiichi Sankyo, BeiGene, Jiangsu HengRui Medicine, Merck Sharp & Dohme, Qilu Pharmaceutical, AstraZeneca, Innovent Biologics, Kartos Therapeutics, Imago BioSciences, Aeglea Biotherapeutics, Akeso Biopharma, Rhizen Pharmaceuticals, Novartis, Amgen, Shanghai Junshi Bioscience, Eli Lilly and company, Impact Therapeutics, Luye Pharma, Pfizer, Genprex and others are evaluating novel small cell lung cancer treatment drugs candidate to improve the treatment landscape.
  • Key Extensive Stage Small Cell Lung Cancer pipeline therapies in various stages of development include LY 2510924, Tiragolumab, BMS-986012, Serplulimab, SYHA1807, BNT411, XmAb18087, Vorolanib, AL3810, LP002, CC-90011, Tremelimumab, ZKAB001, Pembrolizumab, Guadecitabine, KRT-232, Pegzilarginase, Bomedemstat, Tarlatamab, Toripalimab, LY3295668, IMP4297, LY01610, Talazoparib, AK112, RP12146, Sintilimab, and others.
  • In April 2022, Shanghai Henlius Biotech, announced that the New Drug Application of HANSIZHUANG (serplulimab), a novel anti-PD-1 monoclonal antibody (mAb) independently developed by the company, in combination with chemotherapy for the first-line treatment of Extensive-stage Small Cell Lung cancer (ES-SCLC) has been accepted by the National Medical Products Administration (NMPA). Henlius has also planned to file MAA in the EU in 2022. In April 2022, FDA has granted Orphan-Drug Designation for HANSIZHUANG for the treatment of SCLC, benefiting the continuous development of HANSIZHUANG.
  • In March 2022, Akesobio entered into a collaboration agreement with Shenzhen Chipscreen Biosciences to conduct a Phase Ib/II clinical study of combination therapy of Cadonilimab (PD-1/CTLA-4 bispecific antibody, AK104) and Chiauranib (a highly selective Aurora B/VEGFR/PDGFR /c-Kit/CSF1R inhibitor) in patients with ES-SCLC which progressed on combination therapy of platinum-based chemotherapy and PD-(L) 1 inhibitor as first-line treatment.
  • In October 2021, Jiangsu Hengrui Pharmaceuticals reported positive data of a Phase III study, demonstrating that the investigational anti-PD-L1 mAb adebrelimab (SHR-1316) in combination with etoposide and carboplatin (EC) compared with placebo in combination with EC met the primary endpoint of overall survival (OS) as first-line treatment for extensive-stage small cell lung cancer. Hengrui has submitted a pre-New Drug Application meeting request to China National Medical Products Administration based on the positive data.
  • BioNTech is evaluating BNT411 as a monotherapy in patients with solid tumors and in combination with atezolizumab, carboplatin and etoposide in patients with chemotherapy-naïve extensive-stage small cell lung cancer. In July 2021, BNT411 demonstrated an acceptable safety profile at all doses tested as a monotherapy and in combination with atezolizumab, carboplatin and etoposide.
  • In March 2021, China’s National Medical Products Administration cleared Lee’s Pharm to conduct a Phase III, multicenter, randomized, double blinded, parallel-group clinical trial of Socazolimab (anti-PD-L1 monoclonal antibody, formerly known as ZKAB001) combined with chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer.

Request a sample and discover the recent advances in the Extensive Stage Small Cell Lung Cancer treatment @ Extensive Stage Small Cell Lung Cancer Pipeline Outlook

The Extensive Stage Small Cell Lung Cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Extensive Stage Small Cell Lung Cancer products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Extensive Stage Small Cell Lung Cancer pipeline landscape.

Extensive Stage Small Cell Lung Cancer Overview

Extensive Stage Small Cell Lung Cancer (SCLC) is a cancer that has progressed to other parts of the body, such as the other lung or the brain. Without the treatment, the typical Extensive Stage Small Cell Lung Cancer life expectancy is two to four months. With treatment, the Extensive Stage Small Cell Lung Cancer life expectancy climbs to six to twelve months, with a 5-year survival rate of up to 4%.

In the early stage, the person will not have Extensive Stage Small Cell Lung Cancer symptoms. But, as cancer advances, people may develop a chronic cough or recurring lung infections. Extensive-stage small cell lung cancer symptoms are classified as those affecting the lungs, those induced by para neoplastic syndromes (abnormal immunological or hormone activity triggered by the tumor), and those associated with metastasis.

Among the major Extensive Stage Small Cell Lung Cancer causes include smoking. The Extensive Stage Small Cell Lung Cancer diagnosis include several tests such as laboratory test, biopsy, chest x-ray, CT scan, physical exam, sputum cytology, bronchoscopy, and others. The preferred Extensive Stage Small Cell Lung Cancer treatment strategy for the patients is a combination of chemotherapy and immunotherapy drugs.

Find out more about drugs for Small Cell Lung Cancer treatment @ Extensive Stage Small Cell Lung Cancer Drugs

A snapshot of the Extensive Stage Small Cell Lung Cancer Pipeline Drugs mentioned in the report:

DrugsCompanyPhase MoARoA
Serplulimab Shanghai Henlius Biotech Preregistration Programmed cell death-1 receptor antagonists Intravenous
Tiragolumab Hoffmann-La Roche Phase III TIGIT protein inhibitors Intravenous
Socazolimab Lee's Pharmaceutical Phase III Programmed cell death-1 ligand-1 inhibitors Intravenous
Tislelizumab BeiGene Phase III Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants Intravenous
AL3810 Haihe Biopharma Phase II/III Angiogenesis inhibitors; Fibroblast growth factor receptor antagonists; Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c-kit inhibitors; Proto oncogene proteins c raf inhibitors; Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists Oral
QL1706 Qilu Pharmaceuticals Phase II Cytotoxic T-lymphocyte antigen 4 inhibitors; Programmed cell death-1 receptor antagonists Intravenous
BMS-986012 Bristol-Myers Squibb Phase II Fucosyl GM1 ganglioside inhibitors Intravenous
BNT411 BioNTech Phase I/II Toll-like receptor 7 agonists Intravenous
XmAb18087 Xencor Phase I/II Antibody-dependent cell cytotoxicity; T lymphocyte stimulants Intravenous

Learn more about the novel and emerging Extensive Stage Small Cell Lung Cancer pipeline therapies @ Extensive Stage Small Cell Lung Cancer Clinical Trials

Extensive Stage Small Cell Lung Cancer Therapeutics Assessment

The Extensive Stage Small Cell Lung Cancer Pipeline report proffers an integral view of the Extensive Stage Small Cell Lung Cancer emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action, and Route of Administration.

Scope of the Extensive Stage Small Cell Lung Cancer Pipeline Report

  • Coverage: Global
  • Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
  • Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Therapeutics AssessmentBy Route of Administration: Oral, Parenteral, Topical, Intravitreal, Subretinal
  • Therapeutics AssessmentBy Molecule Type: Gene therapies, Small molecule, Polymers, Peptides, Monoclonal antibodies
  • Therapeutics AssessmentBy Mechanism of Action: Programmed cell death-1 receptor antagonists, TIGIT protein inhibitors, Programmed cell death-1 ligand-1 inhibitors, CXCR4 receptor antagonists, Toll-like receptor 7 agonists, Angiogenesis inhibitors, Fibroblast growth factor receptor antagonists, Platelet-derived growth factor-alpha receptor antagonists, Platelet-derived growth factor-beta receptor antagonists, Proto-oncogene protein c-kit inhibitors, Proto-oncogene proteins c raf inhibitors, Type 1 fibroblast growth factor receptor antagonists, Type 3 fibroblast growth factor receptor antagonists, Type-2 fibroblast growth factor receptor antagonists, Vascular endothelial growth factor receptor 3 antagonists, Vascular endothelial growth factor receptor-1 antagonists, Vascular endothelial growth factor receptor-2 antagonists
  • Key Extensive Stage Small Cell Lung Cancer Companies: Genentech, Bristol-Myers Squibb, Henilus Biotech, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., BioNTech SE, Xencor, Inc., Haihe Biopharma Co., Ltd., Taizhou HoudeAoke Biomedical Co., Ltd., Celgene, Xcovery Holding Company, LLC, Lee's Pharmaceutical Limited, Merck & Co, Astex Pharmaceuticals, Daiichi Sankyo, BeiGene, Jiangsu HengRui Medicine, Merck Sharp & Dohme, Qilu Pharmaceutical, AstraZeneca, Innovent Biologics, Kartos Therapeutics, Imago BioSciences, Aeglea Biotherapeutics, Akeso Biopharma, Rhizen Pharmaceuticals, Novartis, Amgen, Shanghai Junshi Bioscience, Eli Lilly and company, Impact Therapeutics, Luye Pharma, Pfizer, Genprex and others.
  • Key Extensive Stage Small Cell Lung Cancer Pipeline Therapies: LY 2510924, Tiragolumab, BMS-986012, Serplulimab, SYHA1807, BNT411, XmAb18087, Vorolanib, AL3810, LP002, CC-90011, Tremelimumab, Ipilimumab, ZKAB001, Pembrolizumab, Guadecitabine, KRT-232, Pegzilarginase, Bomedemstat, Tarlatamab, Toripalimab, LY3295668, IMP4297, LY01610, Talazoparib, and others.

Dive deep into rich insights for new drugs for small cell lung cancer, visit @ Extensive Stage Small Cell Lung Cancer Treatment Drugs

Table of Contents

1. Extensive Stage Small Cell Lung Cancer Pipeline Report Introduction
2. Extensive Stage Small Cell Lung Cancer Pipeline Report Executive Summary
3. Extensive Stage Small Cell Lung Cancer Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Extensive Stage Small Cell Lung Cancer Pipeline Therapeutics
6. Extensive Stage Small Cell Lung Cancer Pipeline: Late Stage Products (Pre-registration)
6.1 Serplulimab: Shanghai Henlius Biotech
7. Extensive Stage Small Cell Lung Cancer Pipeline: Late Stage Products (Phase III)
7.1 Tislelizumab: BeiGene
8. Extensive Stage Small Cell Lung Cancer Pipeline: Mid Stage Products (Phase II)
8.1 BMS-986012: Bristol-Myers Squibb
9. Extensive Stage Small Cell Lung Cancer Pipeline: Early Stage Products (Phase I)
9.1 AK112: Akesobio
10. Extensive Stage Small Cell Lung Cancer Pipeline Therapeutics Assessment
11. Inactive Products in the Extensive Stage Small Cell Lung Cancer Pipeline
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products in the Extensive Stage Small Cell Lung Cancer Pipeline
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

For further information on the Extensive Stage Small Cell Lung Cancer pipeline therapeutics, reach out @ New Drugs forSmall Cell Lung Cancer

Related Reports

Non-Small Cell Lung Cancer (NSCLC) Market

Non-Small Cell Lung Cancer Market Insights, Epidemiology and Market Forecast - 2030 report delivers an in-depth understanding of Non-Small Cell Lung Cancer, historical and forecasted epidemiology current treatment practices, emerging drugs, and key Non-Small Cell Lung Cancer companies involved like Novartis Pharmaceuticals, AbbVie, Janssen Pharmaceuticals, Xcovery, Eli Lilly and Company, Sanofi, Pfizer, and others.

Non-Small-Cell Lung Cancer Pipeline

Non-Small-Cell Lung cancer (NSCLC) Pipeline Insight, 2022, report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Non-Small-Cell Lung cancer (NSCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products, and key Non-Small-Cell Lung cancer companies involved such as GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc, F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Bristol Myers Squibb, Sanofi, and others.

Small Cell Lung Cancer Market

Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the Small Cell Lung Cancer, historical and forecasted epidemiology as well as the Small Cell Lung Cancer market trends, and key Small Cell Lung Cancer companies involved such as Bristol-Myers Squibb, Merck, AstraZeneca, PharmaMar, EpicentRx, and many others.

C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Pipeline

C-Met Mutated Non-Small Cell Lung Cancer Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key C-Met Mutated Non-Small Cell Lung Cancer companies such as Novartis, Apollomics Inc., Abbvie, among others.

EGFR Non-Small Cell Lung Cancer Pipeline

EGFR Non-Small Cell Lung Cancer Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key EGFR Non-Small Cell Lung Cancer companies such as Dizal Pharmaceuticals, Novartis Pharmaceuticals, AstraZeneca, among others.

Artificial Lung Market

Artificial Lung Market Insight, Competitive Landscape and Market Forecast, 2026 report delivers an in-depth understanding of Artificial Lung and the historical and forecasted Artificial Lung market trends, and key players involved such as Xenios, Miromatrix Medical, Lung Biotechnology PBC, Haemair, Michigan Critical Care Consultants, MedArray, Breethe, ALung Technologies, McGowan Institute for Regenerative Medicine, and The Charles Stark Draper Laboratory.

Other Trending Reports

Hypertrophic Scar Market

“Hypertrophic Scar Market” research report delivers an in-depth understanding of the Hypertrophic Scar, historical and forecasted epidemiology as well as the Hypertrophic Scar market size, share, and trends in the 7MM. The key companies in the Hypertrophic Scar Therapeutics Market include Henry Ford Health System, Gladerma, Phio Pharmaceuticals, and others.

Secondary Hyperparathyroidism Market

“Secondary Hyperparathyroidism Market” research report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Secondary Hyperparathyroidism market size, share, and trends in the 7MM. The key companies in the Hypertrophic Scar Therapeutics Market include Sanwa Kagaku Kenkyusho, OPKO Health, TaiRx, Amgen, and others.

Obsessive-Compulsive Disorder Market

“Obsessive-Compulsive Disorder Market” research report delivers an in-depth understanding of the disorder, historical and forecasted epidemiology as well as the Obsessive-Compulsive Disorder market size, share, and trends in the 7MM. Some of the key companies in the Obsessive-Compulsive Disorder Therapeutics Market include Pfizer, GlaxoSmithKline, Eli Lilly and Company, Biohaven Pharmaceuticals, and others.

Degenerative Disc Disease (DDD) Market

“Degenerative Disc Disease (DDD) Market” research report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Degenerative Disc Disease market size, share, and trends in the 7MM. Some of the key companies in the Degenerative Disc Disease Market include DiscGenics, Kuros Biosciences, Mesoblast, Ankasa Therapeutics, and others.

Periodontal Disease Market

“Periodontal Disease Market" research report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Periodontal Disease market size, share, and trends in the 7MM. Some of the key companies in the Periodontal Disease Market include D and D Pharmatech, Amyndas Pharmaceuticals, AngioLab, Denteric, Dexcel Pharma Technologies, Yuhan Corporation, and others.

IgG4-Related Disease Market

“IgG4-Related Disease Market” research report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the IgG4-Related Disease market size, share, and trends in 7MM. Some of the key companies in the IgG4-Related Disease Market include Bristol-Myers Squibb, Xencor, Principia Biopharma, Viela Bio, Horizon Therapeutics, and others.

Nicotine Addiction Market

“Nicotine Addiction Market" research report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Nicotine Addiction market size, share, and trends in the 7MM. Some of the key companies in the Nicotine Addiction Therapeutics Market include Axsome Therapeutics, Achieve Life Sciences, Novo Nordisk, and others.

Related Healthcare Blogs

Small Cell Lung Cancer Treatment Market

Non-Small Cell Cancer Market

Lung Cancer and its Increasing Global Burden

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

For more insights, visit Pharma, Healthcare, and Biotech News

CONTACT: Contact Us

Shruti Thakur

info@delveinsight.com

+1(919)321-6187

www.delveinsight.com

視頻精選
更多新聞